Insider Selling: Sight Sciences (NASDAQ:SGHT) CFO Sells 4,405 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CFO James Rodberg sold 4,405 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $7.82, for a total transaction of $34,447.10. Following the sale, the chief financial officer directly owned 154,440 shares in the company, valued at $1,207,720.80. The trade was a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

James Rodberg also recently made the following trade(s):

• On Tuesday, January 6th, James Rodberg sold 594 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total transaction of $4,443.12.

Sight Sciences Trading Down 3.1%

Shares of NASDAQ:SGHT traded down $0.24 during mid-day trading on Tuesday, reaching $7.47. 197,717 shares of the company’s stock were exchanged, compared to its average volume of 254,706. The firm has a market capitalization of $394.94 million, a price-to-earnings ratio of -8.30 and a beta of 2.42. The business’s fifty day moving average price is $7.47 and its 200-day moving average price is $5.11. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60. Sight Sciences, Inc. has a twelve month low of $2.03 and a twelve month high of $9.24.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) earnings per share for the quarter. The company had revenue of $12.54 million during the quarter. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. On average, research analysts predict that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

A number of large investors have recently bought and sold shares of SGHT. Alliancebernstein L.P. increased its stake in Sight Sciences by 5.5% in the third quarter. Alliancebernstein L.P. now owns 34,380 shares of the company’s stock valued at $118,000 after purchasing an additional 1,800 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Sight Sciences by 32.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after purchasing an additional 2,875 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Sight Sciences by 1.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 303,634 shares of the company’s stock valued at $1,045,000 after buying an additional 3,051 shares during the period. CWM LLC increased its position in Sight Sciences by 70.2% in the 2nd quarter. CWM LLC now owns 7,607 shares of the company’s stock valued at $31,000 after buying an additional 3,137 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in Sight Sciences by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after buying an additional 3,785 shares in the last quarter. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SGHT. Citigroup boosted their price target on shares of Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Lake Street Capital lifted their target price on shares of Sight Sciences from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 21st. UBS Group boosted their target price on shares of Sight Sciences from $7.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Wall Street Zen raised shares of Sight Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Finally, Morgan Stanley lifted their price objective on Sight Sciences from $6.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sight Sciences presently has an average rating of “Hold” and a consensus target price of $8.30.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.